Use of Ependymoma Cell Lines to Test for New Therapeutic VulnerabilitiesEmail Principal Investigator
CBTN Pre-clinical Models
Ependymoma is a disease with nine distinct forms where two of the most common and aggressive forms occur primarily in children. Research into the main drivers of each form has been successful, but there are still very few therapeutic options available to patients. Recent studies have identified vulnerabilities in the ependymoma genome that may pave the way for new therapies. Newly established ependymoma cell cultures from the CBTN will be utilized to validate these discoveries.
What are the goals of this project?
Previous studies have identified ependymoma-specific genes that could serve as targets for gene editing. The project seeks to validate those results.
What is the impact of this project?
Validation of previous research into the genetics of ependymoma could lead to new targets for drug, gene, and immuno-therapy.
Why is the CBTN request important to this project?
The availability of samples needed for this sort of research is limited, so the cell lines provided by CBTN are of high value to this project.
The Children's Brain Tumor Network will contribute to this project by providing cell lines and PDX models.
Ependymomas arise from ependymal cells that line the ventricles and passageways in the brain and the center of the spinal cord. Ependymal cells produce cerebrospinal fluid (CSF). These tumors are classified as supratentorial or infratentorial. In children, most ependymomas are infratentorial tumors